Puzas Álvaro Iglesias, Álvarez Laura Mesa, Menéndez Ángeles Flórez, Romero Yuste Susana, Gómez Olga Prieto
Dermatology Department, Complejo Hospitalario Universitario de Pontevedra, EOXI Pontevedra-Salnés, Pontevedra, Spain.
Rheumathology Department, Complejo Hospitalario Universitario de Pontevedra, EOXI Pontevedra-Salnés, Pontevedra, Spain.
Case Rep Dermatol. 2017 Jul 13;9(2):65-69. doi: 10.1159/000477756. eCollection 2017 May-Aug.
Eosinophilic cellulitis is an uncommon, inflammatory and chronic disorder of unknown etiology. Corticosteroids are currently considered as the first-line treatment but they are not without significant disadvantages such as contraindications in steroid-resistant cases and patients with frequent recurrences. We report a patient suffering from Wells' syndrome with a 24-year history of symptomatic and generalized skin lesions. After consultation in our department, treatment with colchicine 1 mg/day was prescribed resulting in large clinical improvement. No side effects have been recorded. To our knowledge, this is an original disease approach. Although small, our clinical experience supports the inclusion of colchicine in the drug armamentarium when treating patients suffering from Wells' syndrome. Indeed, its excellent safety profile makes it very attractive for patients with frequent recurrent episodes who need secure options for the medium- and long-term disease control.
嗜酸性粒细胞性蜂窝织炎是一种病因不明的罕见、炎症性慢性疾病。目前，皮质类固醇被视为一线治疗药物，但它们并非没有显著缺点，例如在类固醇抵抗病例和频繁复发的患者中存在禁忌证。我们报告了一名患有威尔斯综合征的患者，其有24年的症状性全身性皮肤病变病史。在我们科室会诊后，开具了每天1毫克秋水仙碱的治疗方案，临床症状有了很大改善。未记录到副作用。据我们所知，这是一种新颖的疾病治疗方法。尽管我们的临床经验有限，但支持在治疗威尔斯综合征患者时将秋水仙碱纳入药物储备。事实上，其出色的安全性使其对频繁复发且需要中长期疾病控制可靠选择的患者非常有吸引力。
